Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
Javier De CastroAmelia InsaRoberto Collado-BorrellVicente Escudero-VilaplanaAlex MartínezElena FernandezIvana SullivanNatalia ArrabalDavid CarcedoAlba ManzanequePublished in: BMC pulmonary medicine (2023)
To our knowledge, this is the first study that specifically quantifies the cost of relapse in NSCLC in Spain. Our findings shown that the overall cost of a relapse after appropriate treatment of early-stage NSCLC patients is substantial, and it increases considerably in the metastatic relapse setting, mainly due to the high cost and long duration of first-line treatments.
Keyphrases
- early stage
- small cell lung cancer
- squamous cell carcinoma
- end stage renal disease
- free survival
- ejection fraction
- newly diagnosed
- healthcare
- advanced non small cell lung cancer
- peritoneal dialysis
- sentinel lymph node
- brain metastases
- lymph node
- neoadjuvant chemotherapy
- locally advanced
- replacement therapy
- tyrosine kinase